Evidence map›Paper›PMID 41858071›Full record

ArticleJMIR research protocols2026

Characterizing AIDS Drug Assistance Program Practices and Policies for Sustained Viral Suppression Using the Consolidated Framework for Implementation Research: Protocol for a Qualitative Study.

Kathleen A McManus, Erin Q Rogers, Amber Steen, Amy Killelea, Tim Horn, Reanna Panagides, Steven Laymon, Jessica Keim-Malpass

Abstract read
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathleen A McManusDivision of Infectious Diseases & International Health, School of Medicine, University of Virginia, Charlottesville, VA, United States.ORCID 0000-0001-5786-0018
Erin Q RogersDivision of Infectious Diseases & International Health, School of Medicine, University of Virginia, Charlottesville, VA, United States.ORCID 0000-0003-3189-1558
Amber SteenSchool of Nursing, University of Virginia, Charlottesville, VA, United States.ORCID 0009-0008-9258-0132
Amy KilleleaDivision of Infectious Diseases & International Health, School of Medicine, University of Virginia, Charlottesville, VA, United States.ORCID 0009-0004-5785-918X
Tim HornNational Alliance of State and Territorial AIDS Directors, Washington, DC, United States.ORCID 0009-0002-9960-1588
Reanna PanagidesDivision of Infectious Diseases & International Health, School of Medicine, University of Virginia, Charlottesville, VA, United States.ORCID 0000-0002-2570-3891
Steven LaymonDivision of Infectious Diseases & International Health, School of Medicine, University of Virginia, Charlottesville, VA, United States.ORCID 0009-0004-2753-4464
Jessica Keim-MalpassSchool of Nursing, University of Virginia, Charlottesville, VA, United States.ORCID 0000-0002-7035-8556

Funding

Viral Suppression for People with HIV with Low Incomes: Study of Disparities, Health Equity, and Best PracticesR01AI170093 · NIAID · UNIVERSITY OF VIRGINIA · PI Kathleen Ann McManus · 2023 to 2026
$2.9M
NIAID NIH HHS R01 AI170093
6 · The paper itself

Abstract

backgroundAIDS Drug Assistance Programs (ADAPs), a key part of the federally funded Ryan White HIV/AIDS Program, provide antiretroviral therapy (ART) to low-income and uninsured or underinsured people with HIV. As long as they meet federal regulations, jurisdictions maintain flexibility in implementing ADAPs, allowing for a range of operational and programmatic options, including eligibility criteria, formulary design for ART (and non-ART) drugs, and the nature and character of insurance support. These programmatic and policy decisions ultimately impact ADAP client outcomes, including engagement in care, differences in the populations benefiting from ADAP, and viral suppression rates. Despite ADAPs achieving an 85% national average viral suppression rate, this falls short of the 90% goal needed to end the HIV epidemic, and no formal evaluation has examined how specific operational or policy factors drive success across states.

objectiveThis qualitative study aims to examine how operational, organizational, and contextual factors shape the ability of ADAPs to improve viral suppression rates among people with HIV enrolled in ADAPs, specifically by identifying the mechanisms that facilitate high performance and viral suppression for all people with HIV. Results will inform how viral suppression outcomes could be improved through policy, program, operational, and organizational changes in ADAP design and implementation.

methodsUsing a qualitative descriptive approach guided by the Consolidated Framework for Implementation Research, we conducted semistructured interviews with state-level ADAP leaders, operational and programmatic decision-makers, and staff. Interview questions covered 5 domains: leadership and staffing; operations, integration, and collaboration; formulary design and treatment; eligibility and enrollment; and innovation and implementation. Qualitative data from the interviews will be analyzed using deductive and inductive approaches along with situational mapping.

resultsThis study was funded in April 2023. In total, 33 individuals from 16 states have participated in this qualitative study, resulting in a participation rate of 31.4% (16/51). States from all 4 US census regions were represented. Interviews were conducted between February 12, 2025, and March 20, 2025. As of March 2026, data analysis is underway.

conclusionsWe anticipate that the study will highlight features, organizational practices, and operational norms that contribute to the successes of ADAPs with high rates of viral suppression. Successful completion of this analysis will provide evidence to inform state and federal regulations, program development, resource allocation, and prioritization to advance the goal of helping people achieve viral suppression and interrupt HIV transmission, which is a vital public health objective. Using other data alongside our qualitative findings, we can provide context for the environment in which these programs or policies impact ADAP clients and the broader public health objectives of the Ryan White HIV/AIDS Program. Ultimately, we expect that disseminating these results will support improvements in viral suppression, enhancing both individual health outcomes and public health. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/90008.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsMedical AssistanceSustained Virologic ResponseHumansQualitative ResearchUnited StatesADAPAIDS Drug Assistance Programantiretroviral therapyCFIRConsolidated Framework for Implementation ResearchRyan White HIV/AIDS Programviral suppression

Identifiers

PMID41858071
PMCPMC13133592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.